ClinicalTrials.gg

Program

lotilaner

Also written as “TP-03”, “Low Dose TP-05” and “High Dose TP-05”.

Its studies are mostly in Blepharitis · Rosacea · Meibomian Gland Dysfunction · Lyme Disease · Colitis, Ulcerative, led by 3 companies.

Furthest: phase 3, since Jul 14, 202010 company-led studies, 1 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tarsus Pharmaceuticals81 open or runningphase 3since Jul 14, 2020Jul 14, 2020Dec 31, 2026phase 2 · NCT07443202
LianBio10 open or runningphase 3since Nov 17, 2022Nov 17, 2022none ahead
Zeria Pharmaceutical10 open or runningphase 3since Jul 9, 2013Jul 9, 2013none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 9, 2013First study: phase 3 study in Acute Ulcerative ColitisNew to Zeria PharmaceuticalZeria Pharmaceutical · NCT01903252 · 817 enrolled · Switzerland
  2. Jul 14, 2020Tarsus Pharmaceuticals's first study: phase 3 study in BlepharitisNew to Tarsus PharmaceuticalsTarsus Pharmaceuticals · NCT04475432 · 421 enrolled · United States
  3. Mar 2, 2021Phase 3 study in BlepharitisTarsus Pharmaceuticals · NCT04784091 · 412 enrolled · United States
  4. Jul 22, 20212 phase 1 studies in HealthyTarsus Pharmaceuticals · NCT05138861, NCT05138796
  5. May 3, 2022Phase 2 study in Lyme DiseaseTarsus Pharmaceuticals · NCT05387083 · 30 enrolled · United States
  6. Jun 27, 2022Phase 2 study in Meibomian Gland DysfunctionTarsus Pharmaceuticals · NCT05454956 · 39 enrolled · United States
  7. Nov 17, 2022LianBio's first study: phase 3 study in BlepharitisNew to LianBioLianBio · NCT05629390 · 163 enrolled · China
  8. Jan 31, 2023Phase 1 study in HealthyTarsus Pharmaceuticals · NCT05720364 · 42 enrolled · United States
  9. Feb 24, 2026Phase 2 study in RosaceaTarsus Pharmaceuticals · NCT07443202 · 155 planned · United States

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in RosaceaTarsus Pharmaceuticals · NCT07443202

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07443202Rosacea · United States2By invitationTarsus PharmaceuticalsDec 31, 2026155
NCT05720364Healthy · United States1CompletedTarsus PharmaceuticalsMay 30, 202342
NCT05629390Blepharitis · China3CompletedLianBioSep 15, 2023163
NCT05454956Meibomian Gland Dysfunction · United States2CompletedTarsus PharmaceuticalsMay 18, 202339
NCT05387083Lyme Disease · United States2CompletedTarsus PharmaceuticalsJun 26, 202430
NCT05138861Healthy · Canada1CompletedTarsus PharmaceuticalsSep 3, 202124
NCT05138796Healthy · United States1CompletedTarsus PharmaceuticalsMar 25, 202267
NCT04784091Blepharitis · United States3CompletedTarsus PharmaceuticalsMay 9, 2022412
NCT04475432Blepharitis · United States3CompletedTarsus PharmaceuticalsMay 4, 2021421
NCT01903252Acute Ulcerative Colitis · Switzerland3CompletedZeria PharmaceuticalMay 2016817

How it is read

Names in the registry

  • “TP-03”, 2 entries
  • “lotilaner”, 1 entry
  • “Low Dose TP-05”, 1 entry
  • “High Dose TP-05”, 1 entry
  • “Lotilaner”, 1 entry

Codes read as this program: TP03, TP05.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.